Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Clinical Data

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

 April 16, 2026

Pharmaphorum

Eli Lilly’s ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

Clinical DataMetabolic & GLP-1Read full story

Post navigation

Revolution doubles stock offering target to $2B following pancreatic cancer win →
← FDA accelerated approval path needs improvement, says ICER

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com